-transparent.png){kind=logo}
We describe the occurrence of a lymphoma in a patient with rheumatoid arthritis (RA) taking weekly oral pulse methotrexate (MTX) in low doses for 33 months. This occurrence may be coincidental. There may be an increased incidence of lymphoma in RA not treated with immunosuppressive medications. However, the increasing use of MTX warrants reporting unusual events, especially malignancy. It is possible that even the mild immunosuppression that occurs with MTX therapy places patients with RA at added risk for developing lymphoproliferative diseases.
Related Publications
M H Ellman, and
H Hurwitz, and
C Thomas, and
M Kozloff
March 1993,
Clinical rheumatology,
M H Ellman, and
H Hurwitz, and
C Thomas, and
M Kozloff
June 1998,
The Journal of rheumatology,
M H Ellman, and
H Hurwitz, and
C Thomas, and
M Kozloff
June 2006,
Rheumatology international,
M H Ellman, and
H Hurwitz, and
C Thomas, and
M Kozloff
May 1990,
The Journal of rheumatology. Supplement,
M H Ellman, and
H Hurwitz, and
C Thomas, and
M Kozloff
June 1986,
The Compendium of continuing education in dentistry,
M H Ellman, and
H Hurwitz, and
C Thomas, and
M Kozloff
February 1995,
The Journal of rheumatology,
M H Ellman, and
H Hurwitz, and
C Thomas, and
M Kozloff
June 1992,
The Journal of rheumatology,
M H Ellman, and
H Hurwitz, and
C Thomas, and
M Kozloff
May 2010,
International journal of rheumatic diseases,
M H Ellman, and
H Hurwitz, and
C Thomas, and
M Kozloff
March 1991,
The American journal of medicine,
M H Ellman, and
H Hurwitz, and
C Thomas, and
M Kozloff
October 1993,
Minerva medica,
